Fab’entech
Fab’entech is a French biotech created in 2009 and specialised in the development and production of polyclonal antibodies intended for the treatment of emerging infectious diseases and biodefense solutions. Lifestyles, the globalisation of exchanges, the relationship of humans to nature raise fears of multiplying pandemics in the coming years. Fab’entech offers a modular technological platform which allows the rapid development of effective treatments to deal with the emergence of new infectious diseases or biological threats. The production of polyclonal antibodies by Fab’entech is based on a safe and proven technology, initially developed by Sanofi Pasteur and enhanced for more than 10 years by the Research & Development teams at Fab’entech. Fab’entech thus combines the know-how and experience of a large pharmaceutical company with the agility of a biotech.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Internationally (various countries)
- Year Founded:
- 2009
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
Technology
Fab’entech’s solutions are based on the production of polyclonal antibodies.
These antibodies replace those that the patient has not had time to produce naturally.
They recognise then neutralise the virus or toxin in only a few minutes, thereby stopping disease’s progression.
Polyclonal antibodies
Unlike monoclonal antibodies that attack the virus by targeting a very limited region, polyclonal antibodies attack the virus on several fronts. This allows polyclonal antibodies to remain effective even after virus mutation. Polyclonal antibodies can neutralise a large number of potential variants.
This has notably been demonstrated with the Fab’entech product, Fabenflu®, a polyclonal antibody treatment for the highly pathogenic avian flu virus H5N1, which has the capacity to neutralise more than 20 viral strains from different clades.
To develop these polyclonal antibodies, Fab’entech rigorously selects high-quality antigens to obtain strongly neutralising antibodies.
Lastly, the efficacy of the polyclonal antibodies developed by Fab’entech has been demonstrated on several acute viral diseases: the H5N1 influenza, the Ebola haemorrhagic fever and more recently COVID-19, but also on severe intoxications, proving that these products are particularly well suited to the treatment of medical emergencies.
A safe, recognised and tested technology
Fab’entech’s know-how is based on a safe and tested technology, initially developed by Sanofi Pasteur and enhanced for more than 10 years by the Research & Development teams at Fab’entech. Fab’entech combines the knowledge and experience of a large pharmaceutical company with the agility and innovation of a biotech. Fab’entech has already proven with Fabenflu® that its products are safe in H5N1 patients and has over a decade of expertise in the development of treatments against emerging infectious diseases and bioterror threats.